Purchase this article with an account.
L. Malvitte, D. Gaucher, R. Tadayoni, A. Bron, C. Creuzot-Garcher, P. Massin; Evaluation of the Reproductibility of Repeated Intravitreal Triamcinolone Acetonide for Diabetic Macular Edema. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3464.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To retrospectively evaluate the efficacy and the reproducibility of repeated intravitreal injections of 4 mg triamcinolone acetonide for refractory diffuse diabetic macular edema.
This was a retrospective case series study. Forty-seven eyes of 36 patients with diabetic macular edema unresponsive to laser photocoagulation were included. All patients received at least two injections of 4 mg triamcinolone acetonide. The main outcome measures were the standardized changes in macular thickness (SCMT) measured by Optical Coherence Tomography and the evolution of visual acuity within the 6 months after each injection. Secondary outcomes were intraocular pressure, the rate of cataract surgery performed during the study and the mean time of re-injection
Forty-seven eyes received at least 2 injections; a third injection was performed in 30 eyes, a fourth one in 20 eyes and a fifth one in 12 eyes. The mean interval between injections was 9.1 months. The Central Macular Thickness (CMT) was reduced and visual acuity improved after all injections (p<0.05). The SCMT did not differ significantly whatever the number of injections. Cataract surgery was more frequent in eyes receiving more injections (p=0.001) whereas the increase in IOP was not related to the number of injections.
In the long-term, repeated intravitreal injections of triamcinolone effectively reduced macular thickening due to diffuse diabetic macular edema and improved visual acuity. The rate of cataract surgery increased with the number of injections.
This PDF is available to Subscribers Only